RxDoctor Payments Data

Adrienne Heusmann, PA

Physician Assistant · Crestview Hills, KYNPI 1992229785

Payments from drug & device makers

$3,963in general payments, 2019–2025

Across 208 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$431
  • Lundbeck LLC$332
  • Teva Pharmaceuticals USA, Inc.$255
  • Otsuka America Pharmaceutical, Inc.$214
  • Alkermes, Inc.$178
  • plus $585 from 9 others

What the payments were for

  • Food & beverage$3,963100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,963 in reported general payments places this provider in the 85th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$10,852
Medicare patients
17
Services billed
4,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$102,044
Abilify MaintenaAripiprazole13$37,447
VraylarCariprazine Hcl23$34,398
Lurasidone Hcl18$25,330
TrintellixVortioxetine Hydrobromide17$15,894
Clomipramine Hcl12$9,985
Aripiprazole29$3,247
Bupropion XlBupropion Hcl56$1,989
Buspirone Hcl45$1,360
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$784
Olanzapine12$587
Duloxetine Hcl19$479
Trazodone Hcl35$415
Hydroxyzine Hcl13$364
Venlafaxine Hcl ErVenlafaxine Hcl16$263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$168$102,04412 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$214$37,44713 claims
AbbVieVraylar$1,968$34,39823 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$166$15,89417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Crestview Hills

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →